TONE (NCT01962571) is a prospective, double-blind, randomized, placebo-controlled interdisciplinary study. Goal of the study is to examine whether Erythropoietin (EPO) (33.000 IU) as compared to placebo in addition to steroids has the potential to prevent visual dysfunction and optic nerve degeneration associated with autoimmune optic neuritis.

The primary objective is to determine the efficacy of EPO compared to placebo given as add-on to methylprednisolone as assessed by measures of retinal nerve fiber layer thickness and low contrast visual acuity 6 months after the onset of acute optic neuritis.

The TONE study is sponsored by the German Ministry for Education and Research (BMBF).